Divalproex Sodium Market Dynamics

Increasing prevalence of bipolar disorders around the globe is propelling the Divalproex Sodium Market growth. For instance, according to study published in JAMA Psychiatry Journal 2012, in a combined sample of 61,392 adults from 11 countries, the total lifetime prevalence of bipolar disorder-I was 0.6%, and 0.4% for bipolar disorder-II and subthreshold bipolar disorder was 1.4%, yielding a total prevalence estimates bipolar disorder spectrum of 2.4% globally.

Moreover, rising patient pool around the world affected with epilepsy and migraine headaches is also expected to boost demand for divalproex sodium market significantly. For instance, according to the World Health Organization 2018 key facts, around 50 million people were globally affected with epilepsy, making it one of the most common neurological disease, and around 80% of the people with epilepsy live in low- and middle-income countries.

According to The Migraine Trust Facts and Figures estimates, the global prevalence of migraine was 14.7% for year 2013, that’s around 1 in 7 people. Furthermore, increasing awareness regarding diseases and various government initiatives to prevent head migraine is expected to propel growth of divalproex sodium market size.

However, black boxed warning given by FDA due to the hepatotoxicity, pancreatitis, and high fetal risk associated with the use of divalproex sodium tablet and other known adverse reactions such as birth defects, neurobehavioral adverse effects, and suicidal behavior are expected to restrain the divalproex sodium market growth.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1913

Divalproex sodium is a Food and Drug Administrator (FDA) approved anti-epileptic drug used to treat migraine headaches, manic episodes of bipolar disorders, and certain types of seizures. Divalproex sodium is known for its anticonvulsant properties for the treatment of epilepsy.

Divalproex sodium comes under three dosage forms: capsule, tablet, and syrup. Divalproex sodium oral tablet is available in brand-names, Depakote ER and Depakote. Divalproex sodium is also used in various combinational therapies.

The recommended initial dosage of Depakote for the treatment of bipolar disorders is 750 mg daily, whereas for complex partial seizures, initial dosage starts with 10 to 15 mg/kg/day. Also, recommended starting dose for migraine headache is 250 mg twice daily to achieve therapeutic response.

Divalproex Sodium Market – Regional Insights

Based on the region, the global divalproex sodium market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America, specifically the U.S. divalproex sodium market, holds a major global position among the geographies. Owing to increased government initiatives and rising research and development for the introduction of new product are expected to aid in growth of the divalproex sodium market in the region.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/divalproex-sodium-market-1913

For instance, In 2011 The National Quality Strategy (NQS) was launched as the national strategy for quality improvement in health care, This was led by Agency for Healthcare Research and Quality on behalf of the U.S. Department of Health and Human Services (HHS). However, introduction of generic products by market giants in the region is expected to hamper the market growth in the region. For instance, in 2008, Mylan launched generic of Abbott's Depakote ER in the U.S.

Asia Pacific is expected to show significant growth followed by Europe, owing to increased prevalence of epilepsy and head migraine among the population in the region. For instance, according to study published in the Journal of Global Health 2017, showed that lifetime epilepsy prevalence was 1.99% in 1990 and 7.15% in 2015 among the Chinese population.

Divalproex Sodium Market – Competitive Landscape

Major players operating in the global divalproex sodium market includes Zydus Pharmaceuticals, Inc., AbbVie Inc., Mylan N.V., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Orchid Chemicals & Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Abbott Laboratories.

Market players are engaged in adopting marketing strategies such as mergers, collaborations, induction of new products to their portfolio, and acquisition, in order to obtain dominant position in the market. For instance, in 2017, Zydus Cadila acquired Sentynl Therapeutics, a U.S.-based pharma company specialized in marketing of products in the pain management segment.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1913

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737